Skip to main content

Advertisement

SpringerLink
Log in

New Drugs for Bipolar Disorder

  • Bipolar Disorders (David S. Janowsky, Section Editor)
  • Published:
Current Psychiatry Reports Aims and scope Submit manuscript

Abstract

Bipolar disorder (BD) is one of the most potentially severe mental disorders. Literature data indicate that despite the current available treatments, a large proportion of patients do not achieve complete remission, with consequent residual symptoms and chronic impairment. We carried out a comprehensive review of new pharmacologic treatments for BD. Even though the core treatment of BD likely will not likely undergo substantial changes over the next few years, many promising results with respect to new augmentation strategies were identified. New treatments for bipolar depression and for BD-related cognitive impairment seem to represent particularly fertile areas of research.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Calabrese JR, Hirschfeld RM, Reed M, Davies MA, Frye MA, Keck PE, et al. Impact of bipolar disorder on a U.S. community sample. J Clin Psychiatry. 2003;64(4):425–32.

    Article  PubMed  Google Scholar 

  2. Dean BB, Gerner D, Gerner RH. A systematic review evaluating health-related quality of life, work impairment, and healthcare costs and utilization in bipolar disorder. Curr Med Res Opin. 2004;20(2):139–54.

    Article  PubMed  Google Scholar 

  3. Pompili M, Rihmer Z, Innamorati M, Lester D, Girardi P, Tatarelli R. Assessment and treatment of suicide risk in bipolar disorders. Expert Rev Neurother. 2009;9(1):109–36.

    Article  PubMed  Google Scholar 

  4. • Parikh SV, LeBlanc SR, Ovanessian MM. Advancing bipolar disorder: key lessons from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD).Can J Psychiatry. 2010;55(3):136–43. The authors carried out a summary and critical analysis of the main Systematic Treatment Enhancement Program for Bipolar Disorder findings.

    PubMed  Google Scholar 

  5. •• Sanches M, Newberg AR, Soares JC. Emerging drugs for bipolar disorder. Expert Opin Emerg Drugs. 2010;15(3):453–66. In this review, we discuss some of the novel drugs currently being tested for the treatment of BD, with a focus on their mechanism of action.

    Article  PubMed  CAS  Google Scholar 

  6. Vieta E. Pharmacological management of manic episodes. In: Vieta E, editor. Bipolar disorder in clinical practice. London: Current Medicine Group Ltd; 2007. p. 69–80.

    Google Scholar 

  7. Dennehy EB, Suppes T, Rush AJ, Miller AL, Trivedi MH, Crismon ML, et al. Does provider adherence to a treatment guideline change clinical outcomes for patients with bipolar disorder? Results from the Texas Medication Algorithm Project. Psychol Med. 2005;35(12):1695–706.

    Article  PubMed  Google Scholar 

  8. Gao Y, Payne RS, Schurr A, Hougland T, Lord J, Herman L, et al. Memantine reduces mania-like symptoms in animal models. Psychiatry Res 2011 (in press).

  9. Agarwal V, Tripathi A. Memantine in the management of a clinically challenging case of bipolar disorder. Indian J Psychiatry. 2009;51(2):137–8.

    Article  PubMed  Google Scholar 

  10. Koukopoulos A, Reginaldi D, Serra G, Koukopoulos A, Sani G, Serra G. Antimanic and mood-stabilizing effect of memantine as an augmenting agent in treatment-resistant bipolar disorder. Bipolar Disord. 2010;12(3):348–9.

    Article  PubMed  Google Scholar 

  11. Keck Jr PE, Hsu HA, Papadakis K, Russo Jr J. Memantine efficacy and safety in patients with acute mania associated with bipolar I disorder: a pilot evaluation. Clin Neuropharmacol. 2009;32(4):199–204.

    Article  PubMed  CAS  Google Scholar 

  12. DiazGranados N, Zarate Jr CA. A review of the preclinical and clinical evidence for protein kinase C as a target for drug development for bipolar disorder. Curr Psychiatry Rep. 2008;10(6):510–9.

    Article  PubMed  Google Scholar 

  13. Amrollahi Z, Rezaei F, Salehi B, Modabbernia AH, Maroufi A, Esfandiari GR, et al. Double-blind, randomized, placebo-controlled 6-week study on the efficacy and safety of the tamoxifen adjunctive to lithium in acute bipolar mania. J Affect Disord. 2011;129(1–3):327–31.

    Article  PubMed  CAS  Google Scholar 

  14. Yildiz A, Guleryuz S, Ankerst DP, Ongür D, Renshaw PF. Protein kinase C inhibition in the treatment of mania: a double-blind, placebo-controlled trial of tamoxifen. Arch Gen Psychiatry. 2008;65(3):255–63.

    Article  PubMed  CAS  Google Scholar 

  15. Zarate Jr CA, Singh JB, Carlson PJ, Quiroz J, Jolkovsky L, Luckenbaugh DA, et al. Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study. Bipolar Disord. 2007;9(6):561–70.

    Article  PubMed  CAS  Google Scholar 

  16. Yildiz A, Vieta E, Leucht S, Baldessarini RJ. Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials. Neuropsychopharmacology. 2011;36(2):375–89.

    Article  PubMed  CAS  Google Scholar 

  17. •• Yatham LN, Kennedy SH, Schaffer A, Parikh SV, Beaulieu S, O’Donovan C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord. 2009;11(3):225–55. This is an extensive review of the current FDA-approved and off-label treatments of BD, with specific guidelines targeting the different phases of the disease.

    Article  PubMed  CAS  Google Scholar 

  18. Shen CC, Bai YM, Su T-P. Comment to Dr. Yatham regarding tamoxifen listed as a third-line recommendation for the pharmacological treatment of acute mania. Bipolar Disord. 2009;11:773–5.

    Article  PubMed  Google Scholar 

  19. Machado-Vieira R, Soares JC, Lara DR, Luckenbaugh DA, Busnello JV, Marca G, et al. A double-blind, randomized, placebo-controlled 4-week study on the efficacy and safety of the purinergic agents allopurinol and dipyridamole adjunctive to lithium in acute bipolar mania. J Clin Psychiatry. 2008;69(8):1237–45.

    Article  PubMed  CAS  Google Scholar 

  20. Akhondzadeh S, Milajerdi MR, Amini H, Tehrani-Doost M. Allopurinol as an adjunct to lithium and haloperidol for treatment of patients with acute mania: a double-blind, randomized, placebo-controlled trial. Bipolar Disord. 2006;8(5 Pt 1):485–9.

    Article  PubMed  CAS  Google Scholar 

  21. Eden Evins A, Demopulos C, Nierenberg A, Culhane MA, Eisner L, Sachs G. A double-blind, placebo-controlled trial of adjunctive donepezil in treatment-resistant mania. Bipolar Disord. 2006;8(1):75–80.

    Article  PubMed  CAS  Google Scholar 

  22. O’Brien SM, Scully P, Scott LV, Dinan TG. Cytokine profiles in bipolar affective disorder: focus on acutely ill patients. J Affect Disord. 2006;90:263–7.

    Article  PubMed  Google Scholar 

  23. Brietzke E, Scheinberg M, Lafer B. Therapeutic potential of interleukin-6 antagonism in bipolar disorder. Med Hypotheses. 2011;76(1):21–3.

    Article  PubMed  CAS  Google Scholar 

  24. Citrome L. Iloperidone, asenapine, and lurasidone: a brief overview of 3 new second-generation antipsychotics. Postgrad Med. 2011;123(2):153–62.

    Article  PubMed  Google Scholar 

  25. Bersudsky Y, Applebaum J, Gaiduk Y, Sharony L, Mishory A, Podberezsky A, et al. Valnoctamide as a valproate substitute with low teratogenic potential in mania: a double-blind, controlled, add-on clinical trial. Bipolar Disord. 2010;12(4):376–82.

    Article  PubMed  CAS  Google Scholar 

  26. Kalinichev M, Dawson LA. Evidence for antimanic efficacy of glycogen synthase kinase-3 (GSK3) inhibitors in a strain-specific model of acute mania. Int J Neuropsychopharmacol. 2011 (In press).

  27. Ketter TA. Nosology, diagnostic challenges, and unmet needs in managing bipolar disorder. J Clin Psychiatry. 2010;71(10):e27.

    Article  PubMed  Google Scholar 

  28. Sidor MM, Macqueen GM. Antidepressants for the acute treatment of bipolar depression: a systematic review and meta-analysis. J Clin Psychiatry. 2011;72(2):156–67.

    Article  PubMed  CAS  Google Scholar 

  29. Fountoulakis KN. Pharmaceutical treatment of acute bipolar depression. F1000 Med Rep. 2010;2:47.

    Google Scholar 

  30. Judd LL, Akiskal HS, Schettler PJ, Endicott J, Maser J, Solomon DA, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002;59:530–7.

    Article  PubMed  Google Scholar 

  31. Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, Kronstein P, Khalife S, et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry. 2010;67(8):793–802.

    Article  PubMed  CAS  Google Scholar 

  32. Zarate Jr CA, Quiroz JA, Singh JB, Denicoff KD, De Jesus G, Luckenbaugh DA, et al. An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry. 2005;57(4):430–2.

    Article  PubMed  CAS  Google Scholar 

  33. Brennan BP, Hudson JI, Jensen JE, McCarthy J, Roberts JL, Prescot AP, et al. Rapid enhancement of glutamatergic neurotransmission in bipolar depression following treatment with riluzole. Neuropsychopharmacology. 2010;35(3):834–46.

    Article  PubMed  CAS  Google Scholar 

  34. Berk M, Copolov DL, Dean O, Lu K, Jeavons S, Schapkaitz I, et al. N-acetyl cysteine for depressive symptoms in bipolar disorder—a double-blind randomized placebo-controlled trial. Biol Psychiatry. 2008;64(6):468–75.

    Article  PubMed  CAS  Google Scholar 

  35. Magalhães PV, Dean OM, Bush AI, Copolov DL, Malhi GS, Kohlmann K, et al. N-acetyl cysteine add-on treatment for bipolar II disorder: a subgroup analysis of a randomized placebo-controlled trial. J Affect Disord. 2011;129(1–3):317–20.

    Article  PubMed  Google Scholar 

  36. Dean O, Giorlando F, Berk M. N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. J Psychiatry Neurosci. 2011;36(2):78–86.

    PubMed  Google Scholar 

  37. Fornaro M, Prestia D, Colicchio S, Perugi G. A systematic, updated review on the antidepressant agomelatine focusing on its melatonergic modulation. Curr Neuropharmacol. 2010;8(3):287–304.

    Article  PubMed  CAS  Google Scholar 

  38. Calabrese JR, Guelfi JD, Perdrizet-Chevallier C, Agomelatine Bipolar Study Group. Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data. Bipolar Disord. 2007;9(6):628–35.

    Article  PubMed  CAS  Google Scholar 

  39. Furey ML, Drevets WC. Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial. Arch Gen Psychiatry. 2006;63(10):1121–9.

    Article  PubMed  CAS  Google Scholar 

  40. Nery FG, Monkul ES, Hatch JP, Fonseca M, Zunta-Soares GB, Frey BN, et al. Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study. Hum Psychopharmacol. 2008;23(2):87–94.

    Article  PubMed  CAS  Google Scholar 

  41. El-Mallakh RS, Penagaluri P, Kantamneni A, Gao Y, Roberts RJ. Long-term use of pramipexole in bipolar depression: a naturalistic retrospective chart review. Psychiatr Q. 2010;81(3):207–13.

    Article  PubMed  Google Scholar 

  42. Perugi G, Toni C, Ruffolo G, Frare F, Akiskal H. Adjunctive dopamine agonists in treatment-resistant bipolar II depression: an open case series. Pharmacopsychiatry. 2001;34(4):137–41.

    Article  PubMed  CAS  Google Scholar 

  43. Goldberg JF, Frye MA, Dunn RT. Pramipexole in refractory bipolar depression. Am J Psychiatry. 1999;156(5):798.

    PubMed  CAS  Google Scholar 

  44. Goldberg JF, Burdick KE, Endick CJ. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am J Psychiatry. 2004;161(3):564–6.

    Article  PubMed  Google Scholar 

  45. Zarate Jr CA, Payne JL, Singh J, Quiroz JA, Luckenbaugh DA, Denicoff KD, et al. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol Psychiatry. 2004;56(1):54–60.

    Article  PubMed  CAS  Google Scholar 

  46. Mah L, Zarate Jr CA, Nugent AC, Singh JB, Manji HK, Drevets WC. Neural mechanisms of antidepressant efficacy of the dopamine receptor agonist pramipexole in treatment of bipolar depression. Int J Neuropsychopharmacol. 2011;14(4):545–51.

    Article  PubMed  CAS  Google Scholar 

  47. Drevets WC. Orbitofrontal cortex function and structure in depression. Ann N Y Acad Sci. 2007;1121:499–527.

    Article  PubMed  Google Scholar 

  48. Frye MA, Grunze H, Suppes T, McElroy SL, Keck Jr PE, Walden J, et al. A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression. Am J Psychiatry. 2007;164(8):1242–9.

    Article  PubMed  Google Scholar 

  49. Kumar R. Approved and investigational uses of modafinil: an evidence-based review. Drugs. 2008;68(13):1803–39.

    Article  PubMed  CAS  Google Scholar 

  50. Calabrese JR, Ketter TA, Youakim JM, Tiller JM, Yang R, Frye MA. Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder: a randomized, multicenter, double-blind, placebo-controlled, proof-of-concept study. J Clin Psychiatry. 2010;71(10):1363–70.

    Article  PubMed  CAS  Google Scholar 

  51. Wolf J, Fiedler U, Anghelescu I, Schwertfeger N. Manic switch in a patient with treatment-resistant bipolar depression treated with modafinil. J Clin Psychiatry. 2006;67(11):1817.

    Article  PubMed  Google Scholar 

  52. Ranjan S, Chandra PS. Modafinil-induced irritability and aggression? A report of 2 bipolar patients. J Clin Psychopharmacol. 2005;25(6):628–9.

    Article  PubMed  Google Scholar 

  53. Saricicek A, Maloney K, Muralidharan A, Ruf B, Blumberg HP, Sanacora G, et al. Levetiracetam in the management of bipolar depression: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2011 (in press).

  54. Kraguljac NV, Montori VM, Pavuluri M, Chai HS, Wilson BS, Unal SS. Efficacy of omega-3 fatty acids in mood disorders—a systematic review and metaanalysis. Psychopharmacol Bull. 2009;42(3):39–54.

    PubMed  Google Scholar 

  55. Brown ES, Bobadilla L, Rush AJ. Ketoconazole in bipolar patients with depressive symptoms: a case series and literature review. Bipolar Disord. 2001;3(1):23–9.

    Article  PubMed  CAS  Google Scholar 

  56. Chaves OC, Lombardo LE, Bearden CE, Woolsey MD, Martinez DM, Barrett JA, et al. Association of clinical symptoms and neurocognitive performance in bipolar disorder: a longitudinal study. Bipolar Disord. 2011;13(1):118–23.

    Article  PubMed  Google Scholar 

  57. •• Goldberg JF, Chengappa KNR. Identifying and treating cognitive impairment in bipolar disorder. Bipolar Disord. 2009;11 Suppl. 2:123–13. This is a comprehensive review on the clinical, pathophysiologic, and therapeutic aspects of the cognitive impairment seen in BD.

    Article  PubMed  Google Scholar 

  58. Kelly T. Is donepezil useful for improving cognitive dysfunction in bipolar disorder? J Affect Disord. 2008;107(1–3):237–40.

    Article  PubMed  CAS  Google Scholar 

  59. Gildengers AG, Butters MA, Chisholm D, Reynolds CF, Mulsant BH. A 12-week open-label pilot study of donepezil for cognitive functioning and instrumental activities of daily living in late-life bipolar disorder. Int J Geriatr Psychiatry. 2008;23(7):693–8.

    Article  PubMed  Google Scholar 

  60. Ghaemi SN, Gilmer WS, Dunn RT, Hanlon RE, Kemp DE, Bauer AD, et al. A double-blind, placebo-controlled pilot study of galantamine to improve cognitive dysfunction in minimally symptomatic bipolar disorder. J Clin Psychopharmacol. 2009;29(3):291–5.

    Article  PubMed  CAS  Google Scholar 

  61. Iosifescu DV, Moore CM, Deckersbach T, Tilley CA, Ostacher MJ, Sachs GS, et al. Galantamine-ER for cognitive dysfunction in bipolar disorder and correlation with hippocampal neuronal viability: a proof-of-concept study. CNS Neurosci Ther. 2009;15(4):309–19.

    Article  PubMed  CAS  Google Scholar 

  62. Teng CT, Demetrio FN. Memantine may acutely improve cognition and have a mood stabilizing effect in treatment-resistant bipolar disorder. Rev Bras Psiquiatr. 2006;28(3):252–4.

    Article  PubMed  Google Scholar 

  63. Young AH, Gallagher P, Watson S, Del-Estal D, Owen BM, Ferrier IN. Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder. Neuropsychopharmacology. 2004;29(8):1538–45.

    Article  PubMed  CAS  Google Scholar 

  64. Miskowiak KW, Vinberg M, Harmer CJ, Ehrenreich H, Knudsen GM, Macoveanu J, et al. Effects of erythropoietin on depressive symptoms and neurocognitive deficits in depression and bipolar disorder. Trials. 2010;11:97.

    Article  PubMed  Google Scholar 

  65. Naylor GJ, Martin B, Hopwood SE, Watson Y. A two-year double-blind crossover trial of the prophylactic effect of methylene blue in manic-depressive psychosis. Biol Psychiatry. 1986;21(10):915–20.

    Article  PubMed  CAS  Google Scholar 

  66. Michalak EE, Murray G, Young AH, Lam RW. Burden of bipolar depression: impact of disorder and medications on quality of life. CNS Drugs. 2008;22(5):389–406.

    Article  PubMed  Google Scholar 

  67. Pompili M, Venturini P, Innamorati M, Serafini G, Telesforo L, Lester D, et al. The role of asenapine in the treatment of manic or mixed states associated with bipolar I disorder. Neuropsychiatr Dis Treat. 2011;7:259–65.

    Article  PubMed  CAS  Google Scholar 

  68. Al Jurdi RK, Dixit LA, Sajatovic M. Role of extended release quetiapine in the management of bipolar disorders. Neuropsychiatr Dis Treat. 2010;6:29–35.

    Article  PubMed  CAS  Google Scholar 

  69. Stahl SM. The Prescriber’s Guide. New York: Cambridge University Press; 2009.

    Google Scholar 

  70. Strakowski SM. Approaching the challenge of bipolar depression: results from STEP-BD. Am J Psychiatry. 2007;164:1301–3.

    Article  PubMed  Google Scholar 

Download references

Acknowledgment

Dr. Soares has received grant support from the National Institutes of Health.

Disclosure

Dr. Sanches has served on the speakers’ bureau for AstraZeneca and had travel/accommodations expenses covered/reimbursed by H. Lundbeck A/S.

Dr. Soares has received research grant support from Pfizer, GlaxoSmithKline, Bristol-Myers Squibb, Forest Laboratories, and Repligen Corp.; served on speakers’ bureaus for Eli Lilly and Company and AstraZeneca; and served on a board for DBSA Houston.

Author information

Authors and Affiliations

  1. University of Texas Center of Excellence on Mood Disorders, Department of Psychiatry and Behavioral Sciences, The University of Texas Medical School at Houston, 1541 East Road, Houston, TX, 77054, USA

    Marsal Sanches & Jair C. Soares

Authors
  1. Marsal Sanches
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jair C. Soares
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marsal Sanches.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sanches, M., Soares, J.C. New Drugs for Bipolar Disorder. Curr Psychiatry Rep 13, 513–521 (2011). https://doi.org/10.1007/s11920-011-0231-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11920-011-0231-1

Keywords

Search

Navigation